Geographic Atrophy

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

Anchored matching-adjusted indirect comparison may aid decision-making

Catch up on a few of our top stories and ones you may have missed in 2023

Dr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.

Dr Charles Wykoff discussed the study design and key findings from the GALE study, an extension of the pivotal phase 3 OAKS and DERBY trials for pegcetacoplan in geographic atrophy.

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with Ophthalmology Times about the GALE study data at one year looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.

According to the study, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

Results showed that IZERVAY met the primary objective of reducing the rate of geographic atrophy (GA) growth in patients treated monthly compared to sham-treated patients

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

New drugs are now in the pipeline to focus on treatment of the disease.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

The use of silicone-free syringes advised with these drops.